Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Australia Expects Big Delays to Vaccine Rollout

04/12/2021 | 07:32am EDT

By Mike Cherney

SYDNEY -- Australia expects its Covid-19 vaccination campaign to be delayed by months because of concerns over side effects from the AstraZeneca PLC vaccine and supply-chain issues, in a setback that threatens to extend its border closure and weigh on its economic recovery.

Australia's leaders had planned to have 4 million people vaccinated against the coronavirus by the end of March. But nearly two weeks into April, authorities have vaccinated only about 1.2 million people, or roughly 5% of the population. They had previously said they would aim to vaccinate its entire population by October but now aren't sure when that might happen.

"Rather than set targets that can get knocked about by every to and fro of international supply chains and other disruptions that can occur, we're just getting on with it," Australian Prime Minister Scott Morrison said Monday in a video posted to Facebook. Over the weekend, Mr. Morrison said he now hoped Australians could get a first dose before the end of the year, but he didn't commit to that date and said the government wouldn't set a new target.

Australian officials were relying in large part on the AstraZeneca vaccine because it can be produced locally. But they have blamed the slow rollout on a delay in shipping AstraZeneca vaccines from Europe, which was supposed to boost early vaccination efforts as Australia ramped up its ability to make the vaccines domestically.

The bet on AstraZeneca ran into further challenges last week when Australia's drug regulator said the vaccine should be given only to people over 50 because of the risk of rare but sometimes deadly blood clotting. That forced Australian officials to restrict the rollout of the vaccine, with other countries taking similar steps.

Australia is also administering the Pfizer Inc. vaccine, but all the Pfizer vaccines need to be imported and are also at risk of shipping delays.

The revised timeline for the rollout means Australia's international border, which has been shut to most visitors since the pandemic began and has helped keep the country safe from the virus, could remain closed for longer than expected.

Australian officials previously said the border could be closed for the rest of the year, but an extended closure beyond that would deal yet another blow to tourism businesses that are already struggling and universities that relied heavily on international students.

Australia's economic recovery has been stronger than many forecasters expected, some economists say, driven in part by effective containment of the coronavirus, interest-rate cuts and large government stimulus. There are few coronavirus restrictions in many Australian cities, given that there is virtually no community transmission of the virus, with bars and restaurants largely full and some offices open.

Still, Australian officials have briefly locked down some cities in recent months to prevent small outbreaks from growing, so the virus continues to pose an economic threat. A three-day lockdown in Brisbane, Australia's third-largest city, just before the Easter holiday forced many travelers to cancel their holiday plans. Officials in Sydney locked down parts of the city around Christmas because of an outbreak there.

Economists at Commonwealth Bank recently raised their 2021 growth forecasts to 4.7% from 4.4%, but the vaccination delay increases the coronavirus-related risks to the forecast, said Gareth Aird, head of Australian economics at Commonwealth Bank.

"At the margin, the risk of Covid getting into the community then is obviously a little bit higher," Mr. Aird said.

Even if Australia immediately increased the pace of its vaccinations to match the U.K., where vaccinations are occurring at the second-fastest rate globally, Australia still would still need an extra 116 days to meet its original target, according to an analysis from the McKell Institute, a progressive think tank. It estimated that delay would cost the economy 1.4 billion Australian dollars, equivalent to $1.1 billion, because of more lockdowns.

"I was surprised at the scale of the numbers, and I was also surprised at how bad they got quickly based on the rollout," said Michael Buckland, chief executive at the institute. "As the delays start to accumulate, you start to get some very big blowouts in costs."

Some 30% of visitors to Tropical Fruit World, a tourist attraction in New South Wales state that includes tours of its fruit farm, came from overseas prior to the pandemic, said Sales and Marketing Manager Shona Fuller. She said some group bookings had already come from international visitors for Christmas this year, but she isn't now sure if those people will be able to visit, given Australia's vaccine delay.

"It's really disappointing, to be honest," she said of the delay. "Hopefully it all works itself out and we can start traveling and we can get some international tourists back."

Australia was able to afford a slow start to its rollout because the spread of the coronavirus was largely contained, but officials should have used the extra time to ensure the rollout went smoothly, said Dr. Stephen Duckett, health program director at the Grattan Institute, a think tank based in Melbourne.

"We ended up with both a slow start and a stuffed-up rollout," Dr. Duckett said. "We got the worst of both worlds."

Write to Mike Cherney at mike.cherney@wsj.com

(END) Dow Jones Newswires

04-12-21 0932ET

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.26% 8382 Delayed Quote.14.75%
COMMONWEALTH BANK OF AUSTRALIA 1.04% 105.91 End-of-day quote.28.99%
DJ INDUSTRIAL -0.62% 33823.45 Delayed Quote.12.07%
FACEBOOK INC 1.64% 336.51 Delayed Quote.23.19%
PFIZER, INC. 0.46% 39.48 Delayed Quote.7.25%
All news about ASTRAZENECA PLC
05:17pQuebec minister apologizes for 'communication error' regarding AstraZeneca 2n..
AQ
04:41pCan you mix and match COVID-19 vaccines?
AQ
04:05pCanada Vaccine Panel Recommends Against AstraZeneca PLC for Second Dose
DJ
02:09pUS to Spend $3.2 Billion on COVID Treatments Research
MT
12:00pPFIZER, MODERNA VACCINES NOW PREFERR : Naci
AQ
09:43aAP INTERVIEW : Official says Nepal desperately needs vaccines
AQ
09:37aASTRAZENECAá : UBS Boosts AstraZeneca PT, Maintains Buy Rating
MT
05:47aTHE LATEST : Singer warns UK music festival may get canceled
AQ
03:43aRedx Pharma Gets $4 Million as Milestone Payment From AstraZeneca
DJ
03:34aASTRAZENECAá : UBS maintains a Buy rating
MD
More news
Financials (USD)
Sales 2021 30 988 M - -
Net income 2021 4 559 M - -
Net Debt 2021 10 731 M - -
P/E ratio 2021 36,8x
Yield 2021 2,44%
Capitalization 153 B 153 B -
EV / Sales 2021 5,30x
EV / Sales 2022 4,57x
Nbr of Employees 76 100
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 133,05 $
Last Close Price 116,84 $
Spread / Highest target 46,3%
Spread / Average Target 13,9%
Spread / Lowest Target -17,6%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC14.75%155 589
JOHNSON & JOHNSON4.48%433 009
ROCHE HOLDING AG12.33%333 736
PFIZER, INC.6.76%219 989
NOVARTIS AG1.83%212 691
ABBVIE INC.7.82%204 052